Alexion Pharmaceuticals, Inc announces decision to pause further enrolment in global phase III study of Ultomiris (ravulizumab-cwvz) in adults with severe COVID-19 requiring mechanical ventilation

Independent data monitoring committee recommended that additional enrolment be paused, pending further analysis of the data, due to lack of efficacy when Ultomiris was added to best supportive care, compared to best supportive care alone. No new safety findings were observed.

Source:

Biospace Inc.